#OptometryAdvisor
LightNews LightNews
optometryadvisor.bsky.social
The @US_FDA approved Ranluspec™ (ranibizumab-hkdz), an interchangeable biosimilar to Lucentis®, for the treatment of multiple retinal diseases.

Learn more: https://bit.ly/4qYjzbT

#OptometryAdvisor
FDA Alerts: New Optometry Drugs and Devices
This roundup highlights recent FDA updates related to drug approvals and devices used by optometric eye care professionals.
bit.ly
June 17, 2026 at 6:15 PM
optometryadvisor.bsky.social
Jeffrey Sonsino, OD, examines advocacy wins, vision benefit manager reform, and the ongoing fight for optometry's future. @optometryadvisor.bsky.social

Read more from Dr Sonsino: https://bit.ly/4odChfw

#OptometryAdvisor
Optometry’s Recent Legislative Wins Show, Progress Is Earned, Not Granted
Jeffrey Sonsino, OD, a member of the AOA’s Federal Relations & Advocacy Committee, reviews recent legislative wins by organized optometry.
bit.ly
June 5, 2026 at 3:49 PM
optometryadvisor.bsky.social
Patients with #Glaucoma may experience visual difficulties differently depending on where their #VisualField damage occurs, research in Optometry and Vision Science suggests.

Read more: https://bit.ly/4uzPQHT

#OptometryAdvisor
Central, Inferior Glaucoma Visual Field Loss Lowers Quality of Life
Central and inferior visual field loss from glaucoma are linked to greater reductions in vision-related quality of life than other defects.
bit.ly
June 4, 2026 at 5:08 PM
optometryadvisor.bsky.social
A novel spectacle lens designed to induce peripheral myopic defocus significantly slows #MyopiaProgression and #AxialElongation older than 24 months in #ChildrenWithMyopia, according to study findings published in Eye.

Learn more: https://bit.ly/3PVaofC

#OptometryAdvisor
Novel Spectacle Lens Slows Myopia Progression and Axial Elongation in Children
A novel spectacle lens designed to induce peripheral myopic defocus can significantly slow myopia progression in children over 24 months.
bit.ly
June 3, 2026 at 8:24 PM